valu usd unless otherwis note
 inflect innov high growth
base initi op target
view recent strateg move jv consum busi
separ upjohn left near-term step messi set-up
weigh share sentiment set emerg best-in-class
growth stori smaller innov base under-lev balanc
sheet deploy revers overdon out-year loe concern top
idea larg cap pharma coverag initi op
recent strateg move leav best class growth platform smaller
base model revenu ep compound-annual-growth-rate
margin set materi kick basi point expans
upjohn re-set driven product mix oper
leverag set becom smaller base best sector
growth also see portfolio lower risk loe next
year think improv visibl upjohn separ
serv catalyst share
physician call survey work leav us bullish upsid potenti
vyndaqel ibranc potenti drive revis
overal core five product drive close half revenu
compound-annual-growth-rate pipelin ad addit option
taken deep dive look vyndaqel ibranc xeljanz eliqui
prevnar product model physician survey and/or call
come street vyndaqel ibranc adjuv
palla data read latter lower risk import trigger
upward ep revis vyndaqel survey support view
meaning ramp attr-cm diagnosi rate support expect
one import product driver
loe concern overst like lift deploy
meaning loe impact leav long runway
meaning firepow end net debt deal activ
pick pipelin build expect bear case loe soften
model ad risk adjust pipelin hole fill
billion billion keep compound-annual-growth-rate could simpli
buy prefer pipelin build strategi pursu via smaller
mid-stag asset bring shot goal less execut risk
myl/upjohn effect provid dividend per
share valu upjohn revers morri trust newco
viatri impli ownership provid holder effect
dividend mid-year deal close worth today
price target also see cash infus billion
de-lev compani upjohn separ
see sustain dividend yield put near sector high
price prior trade day market close estimate unless otherwis note
gsk consum joint ventur close upjohn
revers morri trust expect remain
stand-alone compani well-posit bolster
balanc sheet improv organ growth profil
abil strateg invest futur growth thesi
base follow key point support
recent deal dilut earn
remain base differenti science-focus
higher growth compani drive mid-singl digit
growth compound-annual-growth-rate like strateg move
shrink grow via consum busi joint ventur
revers morri trust upjohn busi
messi near-term leav stronger base
grow
see upsid vyndaqel ibranc rel
consensu top five product compris almost half
base solid underli growth
bottom line
bear case point loss exclus loe
beyond ampl time back-fil revenu base
grow dividend under-lev base strateg
decis pursu bolt-on deal rather mega merger
bring lower risk ampl time back-fil well understood
anticip loe
potenti catalyst close upjohn rmt mylan
expect stand-alone guidanc
jan data read focu ibranc palla penelop
compar head-to-head result expect
risk thesi delay close upjohn spin
competit risk key product like ibranc prevnar
slower-than-expect uptak growth driver
vyndaqel xeljanz eliqui regulatory/pr risk
read-through price includ market china
bloomberg capit market estim upside/downside/target
base case scenario see price target impli
price-to-earnings pro-forma ep
assum close upjohn revers morri trust
rmt cash proce go toward debt
paydown specif built estim
expect continu capit deploy annual
dividend growth bd stock repurchas
strong uptak key growth product vyndaqel
success convers key pipelin opportun
upsid case scenario see price target impli
price-to-earnings pro-forma ep
assum close upjohn spin mylan
stronger-than-expect growth key product
success convers key pipelin opportun
downsid case scenario see price target
impli price-to-earnings pro-forma ep
assum close upjohn rmt mylan
sluggish uptak key product vyndaqel
disappoint key pipelin data read ibranc
aggress price action china expect
valu pfizer
investor pend upjohn
spin via revers morri trust
 newco
follow agreement pursu
joint ventur consum
busi revers morri trust
upjohn remain-
co growth profil look
follow separ upjohn busi via revers morri
trust holder left ownership newco receiv
billion cash upon close expect current stock price
impli valuat newco name viatri ebitda
think move higher current level would impli valu pfizer
holder closer per share valu mylan reach target
newco also expect pay dividend combin dividend
keep combin distribut roughli level
recent transact streamlin remain innov
biopharma segment posit strong multi-year growth pfizer
organ revenu earn compound-annual-growth-rate respect
follow close upjohn transact one driver behind robust
growth lack materi loss exclus key product
period though pick growth outlook
potenti improv see upsid compani
initi point potenti blockbust opportun pipelin
could hit also model explicit busi develop
properli posit
benefit signific growth
opportun expect come
china meaning
meaning exposur china billion revenu
half remain follow upjohn spin billion
compris biopharma revenu go-forward growth profil
segment believ greater also plan file
new product next year china importantli infrastructur
place thousand rep expect compromis
separ upjohn busi
meaning could
adjuv opportun
ibranc think
competit posit
product
ibranc remain market leader inhibitor metastat
breast cancer mbc focu adjuv trial think could
potenti doubl opportun palla penelope-b set read
like late enrol report growth
model continu given risk-adjust credit
adjuv earli breast cancer opportun eli lilli verzenio adjuv
trial monarch report data novarti kisqali natale trial farther
behind file expect earli
aggress plan
capit deploy
next year
compani need start ramp
deal anticip
unlik peer limit loe concern near-term allow
take balanc view capit deploy focu bolster
mid-stag pipelin deal around phase capit deploy strategi
next year focus continu growth dividend ii
debt paydown billion receiv newco/viatri connect
upjohn separ go toward repay iii though larg deal
unlik focu earli mid-stag deal key therapeut area
tabl content
outperform price target portfolio manag summari
growth smaller base set inflect improv margin stori
core product revenu see upsid vyndaqel ibranc
hit post cash deploy pipeline/d add support
street sentiment mix stock headwind post recent strateg move
see valuat upsid sever move part consid
deriv cross-read keep focu
catalyst calendar limit post recent approv watch competitor data
import risk consid rel rate price target
financi model revenu build balanc sheet cash flow forecast
appendix deeper look vyndaqel expect rapid uptak
appendix deeper look ibranc palbociclib adjuv key growth
appendix deeper look prevnar focu approv
appendix deeper look xeljanz see stabl growth late loe
appendix deeper look eliqui high margin contribut
report price market close unless otherwis state
outperform price target portfolio manag summari
like best class revenu ep growth group averag valuat
follow strateg move separ consum upjohn busi remain
lean busi come robust growth meaning oper leverag
sentiment name notabl low follow ep step-down well
understood under-lev balanc sheet
healthi deal appetit mid stage pipelin asset five year introduc next wave
growth driver compani tactic begin deploy capit think valuat
follow potenti improv sector-high ep compound-annual-growth-rate
exhibit forecast versu street street forecast notabl mix includ upjohn despit
separ pend via revers morri trust form viatri
consum busi
 set inflect best class growth limit loe risk like
strateg move send
joint ventur
glaxosmithklin form newco combin upjohn busi
two move leav leaner faster grow despit ep step-down
deliv revenu compound-annual-growth-rate realist expect
drive ep compound-annual-growth-rate back one sector best margin stori given
mix shift higher margin product notabl oper leverag
core product compris roughli half busi collect grow
growth led vyndaqel ibranc
respect street see potenti upsid
biggest mover like come ibranc back anticip
palla trial street model reflect continu growth think
favor updat would push forecast higher rel low risk data
pipelin remain swing factor sever product add
growth risk adjust model
biggest debat like remain around compani abil grow
time-frame would say two thing first sentiment around
name low think primarili reflect concern second under-
lever balanc sheet focu acquir mid-stag pipelin target five
year see busi develop activ pick think sentiment potenti
improv meaning pipelin support said differ per analysi
would need gener billion revenu support back-fil
order maintain robust growth time period would
need find billion new revenu sourc
includ upjohn mid mix difficult post-upjohn base
balanc sheet offer meaning fire power deal think
under-appreci pfizer net lever end reflect
receipt billion proce upon close upjohn deal leav
billion cash flow capital-expenditure dividend deploy
includ potenti monet consum busi
partner glaxosmithklin publicli messag happen insid
potenti ad anoth billion billion pre-tax proce word
see meaning option smaller faster grow base allow
grow post
exhibit broken product biopharma busi given pend separ upjohn
therapeut area revenu total revenu total cagrcommentsintern medicineeliqui apixiban loe ibranc palbociclib year growth driven adjuv usextandi enzalutamid mdvn deal sept juli led sulperazon hospit product segmentpf centreon busi acquir fragment segmentvaccin prevnar expect extend adjust includ xeljanz tofacitinib end remicadeabrocitinib approv atop dermatitisenbrel enter franchis diseas vyndaqel tafamadi earli launch drug
growth smaller base set inflect improv margin stori
ep compound-annual-growth-rate
stock seen neg reaction level sinc announc
intend split slower grow upjohn busi move combin
format joint ventur glaxosmithklin combin consum busi
effect creat smaller faster grow base stronger balanc sheet
invest growth consum deal close upjohn expect
close leav roughli flat earn see revenu
ep compound-annual-growth-rate move lower revenu and/or earn
creat robust growth stori smaller base set
focus growth core biopharma busi
pfizer earn growth near top peer averag
expect ep compound-annual-growth-rate per factset consensu estim second closest
compani consensu ep compound-annual-growth-rate moreov estim
exclud impact accret bolt-on area expect compani
remain activ understand push-back around ep re-set
point ep floor ex-upjohn compound-annual-growth-rate well consolid
earn growth upjohn includ
exhibit bottom forecast ep compound-annual-growth-rate
uniqu rel benign headwind loss exclus
help explain pfizer favor growth profil rel peer
per exhibit manag per model abl larg off-set via
pipelin new launch growth gener conserv forecast
also remov temptat pressur follow peer bristol-my squibb abbvi
pursu larg transact plug instead expect continu
bolt-on strategi help build pipelin
exhibit pfe cumul exclud certain smaller product
individu model
pfe share
consum jv gsk
could worth billion
time expect de-
merger
consum busi billion revenu longer
report pfizer consolid result assum high teen oper margin
tax ep contribut recogn share
earn joint ventur incom line indic expect
slightli accret first three full year thing structur
lower revenu margin ep accret short term ii
glaxosmithklin intend separ demerg within three year
reiter latest earn call would effect creat cash opportun
assum consum sale multipl forecast
pfizer stake could bring cash proce billion next coupl year
expens ep dilut
exhibit think pfe share consum jv gsk could worth close billion time-frame
gsk jv incom revenu gsk/ jv growth see low-to-mid singl digit growth realistictot oper target ipo/spin w/in op margin jv mid-to-high share ownership share per deal gsk after-tax per guidanc jv incom tax corp ratep share contribut total valuecomp incl pg ulvr-gb rb-gb cl chdmedian global consum peer ulvr pg impli valu gsk plan ipo/demerg w/n global consum peer ev/op asset lever prior demergerimpli valu retain option particip via demerger/saleaverag share could worth
spin-off upjohn revers morri trust bring equiti distribut
newco sharehold also billion cash infus via newco debt
upon close cash upon close help de-lev turn
ev/ebitda term ep step-down upjohn link dilut manag
provid floor guid impli billion revenu outlook
mid incom tax ibt margin expect proper guidanc result
believ ex-upjohn conserv line sand debat
time divestur upjohn lowest multipl specialti pharma environ
seen help pivot lyrica loe re-set base busi
boost five-year compound-annual-growth-rate higher
exhibit expect becom margin expans stori post-upjohn close ibt
margin shown base year
expect gener oper leverag across peak
incom tax ibt margin us import part stori
earn growth exhibit detail bridg
expect ibt margin increas nearli basi point surprisingli two largest
contributor sg capit revenu compound-annual-growth-rate
also model gross margin expans driven favor product mix grower like
vyndaqel xeljanz eliqui bring corpor averag margin
incom categori includ incom consum healthcar joint ventur also
contribut growth albeit lesser degre margin receiv jv partner
exhibit model bp total ibt margin expans
come sg oper leverag
core product revenu see upsid vyndaqel
prevnar xeljanz
compris
revenu grow five-
year compound-annual-growth-rate
highli diversifi broad biopharma platform compani five
largest product drive close half revenu pro-forma mid-year close
upjohn vyndaqel ibranc prevnar xeljanz eliqui collect
grow compound-annual-growth-rate none loe leav import driver
next five year put lack loe risk asid host data updat
competit event drive path detail
watch exhibit product model bigger deep dive
think vyndaqel ibranc deliv upsid flat slightli
street three two product also fastest grow five-year
cagr respect vyndaqel recent launch approv
therapi attr-cm annual price per patient provid meaning
upsid success drive diagnosi higher vyndaqel drive ep
upsid versu street per exhibit ibranc current within metast breast
cancer bigger opportun deliv posit data approv adjuv use
data palla studi expect later year earli potenti
earlier interim read debat much street alreadi
built think small amount rel patient pool doubl
mbc current street ep relat ibranc
see favor approv think could anoth ep alon
reflect doubl revenu though model revenu doubl
exhibit ep differenti versu street key product note
ep impact reflect variou gross margin base split uniform tax
assumpt appli
exhibit top product compris close half revenu base
productstatusdiseaseketcompetitiontri watchsal outlook vyndamax tafamadi attr-cm approv us may japan attr-cm file eu jan hattr-pn approv countri includ eu japan amyloid cardiomyopathi attr-cm -amyloid fibril deposit heart caus stiffen lead failur year life expect diagnosi -for polyneuropathi delay loss peripher nerv function adult famili amyloid polyneuropathyattr-cm patient ww us wild type hereditary/mut attr-polyneuropathi ww annual pricepolyneuropathi attr-cm competitor off-label use-onpattro alnylam vutrisiran alnylam tegsedi akcea develop comp includ akcea-ttr-lrx apollo-b helios-b akcea-ttr-lrx/ion-ttr-lrx phase ibranceibr approv us combo use metastat breast cancer mbc treatment approv eu adjuv use current evalu clinic trial drive next leg growthmbc stage iv breast cancer breast cancer metastas unlik cure therapi focu prolong surviv ibranc indic mbc account breast cancersoveral breast cancer preval estim million women us women compris major breast cancer patient de novo mbc mbc recurr breast cancer becom metastat verzenio abemaciclib novarti kisqali ribociclib approv inhibitor verzenio greater sharekey adjuv trial ibranc palla penelop primari complet estim competitor trial includ verzenio monarch primari complet kisqali natale primari vaccin approv prevent pneumococc pneumonia indic adult pediatr use candid prevnar current ph adult ph pediatricpneumococc diseas infect caus streptococcu pneumonia bacteria bacteria caus mani type ill includ pneumonia bacteremia sepsi mening young children elderli certain at-risk adult susceptibleal children certain higher-risk adult recommend receiv pneumococc immun global coverag among old estim whopneumovax also approv adult merck develop multipl next-gen pneumococc vaccin candid includ phase adult/pediatr adult popul onlyprevnar three on-going ph trial adult one on-going ph trial pediatr on-going ph approv us rheumatoid arththriti addit xeljanz approv psoriat arthriti ulcer coliti on-going phase studi ankylos spondyl xeljanz approv eu japanjak/stat pathway implic multipl cytokin signal path inhibit jak/stat signal may dampen autoimmun variou disord ra first indic character inflamm synovium damag joint bone cartilagew see xeljanz address non-respond biolog gener given moderate-to-sever patient estim moder sever patient receiv biolog patient non-respond appli similar assumpt across autoimmun disordersw believ competitor includ jak inhibitor span select non-select includ baricitinib ruxolitinib olacitinib non-select upadacitinib filgotinib abrocitinib select filgotinib phase select data uc rinvoq phase data phase data long-term safeti studi xeljanz baricitinib approv reduc risk stroke system embol patient nonvalvular atrial fibril also approv prevention/treat deep vein thrombosi dvt pulmonari embol pe atrial fibril af quiver irregular heartbeat led blood clot stroke heart failur heart-rel condit stroke prevent princip prioriti manag afther estim million peopl us af includ approxim peopl age year older approxim af patient valvular af variabl due lack uniform definit noac market competit four fda-approv drug market pradaxa xarelto savaysa bevyxxa addit warfarin still play promin role though market share declin eliqui competitor conduct wide varieti addit clinic studi variou indic none overli materi
hit post cash deploy pipeline/d add support
loe
hit
benefit rel next five year contribut
steadi growth rate start revers late xeljanz goe
patent us continu addit see exhibit
notabl project period includ prevnar eliqui xtandi
ibranc vyndaqel includ xeljanz six product
collect account revenu much need replac
prevnar except assum switch view
effect backfil revenu combin intern pipelin
convers bolt-on like remain one biggest debat
exhibit loss exclus limit reduc gap-fil need
larger financi driven million
note exclud smaller product individu model
even without upjohn plenti firepow pursu
 fill loe gap exhibit show expect capit alloc per
model account dividend averag billion per year leftov
free cash flow billion grow billion assum
billion alloc share repurchas year realiti number
flex base need leav signific financi resourc
continu execut strategi bolt-on moreov net leverag
fall also ampl flexibl lever right opportun
exhibit strong free cash flow growth provid ampl
resourc pursu and/or share repurchas
expect maintain gener albeit modestli lower dividend follow
upjohn deal close promis keep sharehold whole respect
newco
mylan/upjohn per analysi exhibit sharehold expect receiv
around annual dividend newco current annual dividend
per share would therefor expect step roughli upon upjohn
deal close around move per quarter per quarter
includ dividend paid remainco
exhibit pfizer sharehold expect receiv annual newco dividend
result dividend yield still place upper end peer
shown exhibit us import differenti stori
newco pro-forma dividend analysisannu free cash flow dividend pay-out annual sharehold ownership sharehold share newco share count newco dividend per
exhibit comparison large-cap biopharma dividend yield rank top half
estim need find revenu billion keep revenu
flat level contrast grow top-line compound-annual-growth-rate would
need sourc revenu billion illustr exhibit purpos
analysi pull revenu directli dcf includ contribut
current market product intern pipelin step-down driven
put differ shade area revenu need replac via
and/or un-risk adjust pipelin move commerci
exhibit approxim billion revenu need backfil order
expect pick-up smaller deal target mid stage pipelin product
front key improv sentiment around back-fil
clear focu find next array-lik deal instead see
deal like vivet therapeut therachon akcea per exhibit effect abl
product find target pick-up phase data read next two
four year emerg catalyst stock assuag loe concern
exhibit manag point futur deal similar size strategi vivet therachon akcea
expect focu mega merger possibl go away compani
clear focu pull togeth recent commentari four
differ execut recent month consist around smaller type deal
compani interest per exhibit
announc target-price paid/receivedlead drug therapeut area commentsapril allogenepf hold ownership receiv right preclin asset clinic assetdecemb ventur gskwill jvseveralconsumerslightli accret first yr closemarch million up-front add diseaseinclus option exercis payment acquir vivetmay million up-front add million diseasewil spin apraglutid develop program separ compani hold minor stakejun biopharmapaid billion enterpris valu mektovioncologyneutr ep accret start newco billion cashseveralgenerics/off-pat all-stock revers morri trust expect close licens dealpaid million up-front billion mileston diseasein phase data expect earli
exhibit manag consist clear interest pursu larg scale
includ risk adjust contribut pipelin model focu
pipelin go appropri high import data read exist
product import palla studi ibranc also
new product opportun watch per exhibit overal exclud contribut
array billion new product new expand indic launch revenu
built risk adjust basi roughli million abrocitinib
seem like larg number billion base realli per prior
analysi need add billion model order keep
base flat grow
venuecom investor earn look deploy capit busi develop would mid-phas product target like product could launch mid-next decad product gener within five key therapeut area focus smaller deal dec chuck triano ir someon ask us would anoth array billion brought us nice pipelin less like someth like probabl like see next coupl year make math easi say number million deal rather one billion deal think smaller in-licens mayb tuck-in certainli term size continu consid bolt-on gener dont comment specif size think would say asset rang billion dollar would continu consid bolt-on acquisit realli complement pipelin excit opportun that someth particularli go focus month ahead april john young chief busi offic noth chang deal way see busi develop go forward see activ bd continu activ bd said prefer bolt-on opportun early-to-mid stage opportun mayb higher risk know valu creation greater risk oper disrupt much lower philosophi continu regard larg scale said never say never right opportun advanc pipelin uniqu still see need larg deal right creat disrupt term size like vivet therachon one last thing say look big deal never get time get ask alway get ask big deal look big deal look megad sept frank amelio cfo investor confer juli albert bourla ceo exhibit pipelin asset
ibsadatop dermat us uc cd vitiligooa sign symptom chronic fl back pain cancer painbavencionashaa pso uc cd vitiligo rcc inlyta combo ad nsclc gc urothelialdaurismodm type local advanc scc aml ldac combo hormon sensit pc eu bavencioinflammatori disordersaml combovyndaqelcombo cancer solid tumor us httr-polyneuropathi eu combo cancernashhigh risk earli bc earli nsclc us combo cancer solid tumor metastat castration-resist pccombo mcc solid tumor combo advanc metasta metastat hormon sensit cancersolid tumor combo solid tumor pc us non-metastat high brca atm defect combohormon sensit pccancerdaurismofidanacogen metastat castration-resistantscd assoc acut vaso-occlus cancerpc germlin brca mutant local tn growth hormon clostridium difficil non-invas non-invasivegram-neg bacteri infectionsbc metastaticpneumococc induc cell inflammatori demyelin group abcwi cancersphas areata ad atop dermat aml acut myeloid leukemia ankylos spondyl attr-cm transthyretin amyloidosi cardiomyopathi hattr hereditari transthyretin amyloidosi bc breast cancer cd crohn diseas dm diabet mellitu dmd duchenn muscular dystrophi fl follicular lymphoma fsg focal segment glomerulosclerosi ibd inflammatori bowel diseas ldac low-dos cytarabin mm multipl myeloma ms myelodysplast syndrom nash non-alcohol steatohepat nsclc non-smal cell lung cancer pc prostat cancer psa psoriat arthriti pso psoriasi ra rheumatoid arthriti rcc renal cell carcinoma uc ulcer colitistherapeuticseg inflamm immunolog intern medicin oncolog diseas vaccin hospit anti-infect
street sentiment mix stock headwind post recent strateg move
share trade sinc juli upjohn deal announc limit
recoveri seen thu far trade day announc drg flat
week drg investor digest deal deal help pfizer
de-lev billion cash receiv deploy toward debt paydown
slim busi sustain higher-growth busi also come
meaning impli ep step-down add spotlight
given smaller base pushback deal center around point
manag clear intent deploy capit toward bolt-on earlier
stage deal rather backfil dilut inorgan despit question seem
recur furthermor sharehold made whole dividend
commit grow dividend typic annual increas
seen past
overal glaxosmithklin joint ventur upjohn announc leav
cleaner nimbl platform well-posit near-term fundament concern
loe cliff persist consensu number around still messi clearli
need reset said still see disloc stock today
fundament valu compani mid-singl digit growth outlook flexibl around
strateg capit deploy posit sever long-term shot goal perpetu
growth understand focu
exhibit share declin meaning upon upjohn deal announc
declin week rel drg limit recoveri sinc
share trade
upon upjohn deal
announc
limit recoveri thu
street number still messi ep span wide rang per exhibit estim
start revis lower though ep rang remain wide
manag set floor ep number biopharma busi ex-
upjohn upjohn spin expect close think ep bogey
conserv complic factor upjohn contribut
move part name step-down busi lyrica loe china pressur
also undoubtedli dis-synergi involv separ busi
even though manag point rel independ upjohn intern leav
next year transit year low visibl ep think ad somewhat
neg sentiment chang beyond
exhibit street ep still mix upjohn deal
street ep remain
mix inclus
upjohn expect
becom part newco
sell-sid rate also follow fewer rate equival buy per
exhibit rate effect buy june also
lower compar peer merck respect
exhibit sell-sid rate time buy equival rate reduc
slowli move lower reflect remov upjohn busi time ad confus
see valuat upsid sever move part consid
price target
base valu
attribut remainco
valu
associ
price target compris remainco valu base equal blend
ev/ebitda price-to-earnings estim attribut sharehold
ownership stake newco mylan/upjohn remainco use ev/ebitda
get us per share price-to-earnings get us per share use
expect capit structur contempl upjohn exit
sharehold also newco worth approxim billion per
share calcul use price target separ ran discount cash flow
analysi dcf get us per share slightli stand-alone remainco
remainco target multipl function larg cap pharma price target
framework exhibit start histor three-year industri averag multipl
adjust company-specif factor adjust combin form net
premium mark re-rat higher rel histor valuat rang
see exhibit believ justifi larg part remainco favor growth
 track record remain well-posit continu strategi
pursu bolt-on moreov like strateg merit compani decis
form consum healthcar joint ventur glaxosmithklin ii separ
upjohn busi collect leav smaller faster grow base
dividend yield even modest haircut post-upjohn separ project
dividend yield rank top half peer
growth profil model revenu compound-annual-growth-rate
combin oper leverag growth incom drive ep compound-annual-growth-rate
period well peer see exhibit
loe risk concentr face major
xeljanz multipl major hit includ eliqui
ibranc vyndaqel compani long-term outlook depend abil backfil
new launches/m
exhibit larg cap pharma price target framework company-specif adjust collect equat
valuat premium rel histor industri averag note add reflect stake
note abbvi forecast pro-forma pend allergan transact
dcf part price target yield valu per share dcf
reflect explicit forecast termin growth rate beyond use
wacc consist across large-cap pharma coverag termin growth
forecast highest among large-cap biopharma coverag justifi
view depth pipelin lower earn base get past major
dcf also exclud valu attribut mylan/upjohn although
account billion debt proce receiv remainco within
p/eev/ebitda averagem track recorddividend yieldgrowth profilelo risk p/eev/ebitdashar cap net debtenterpris valueshar estimate net leverageimpliedotherpriceimplieddebt adj target adjust price target repres addit valu relat myl/viatri contribut captur estim forecast total averageadjust factor /- valuat
exhibit dcf deriv valu per share wacc termin growth
exclud sharehold valu mylan/upjohn million except per
pv termin valueperpetu growthenterpris equiti valueequ valu per
sharehold also ownership newco ventur
current per share reflect billion proce pfizer
upon close via new debt newco captur capit structur
compani upon close holder new compani billion
share current price per share impli valu
move closer price target believ deal close would
push valu closer per share exhibit show valu holder could
theoret move closer bullish valuat scenario newco
exhibit price target would impli valuat sharehold
per share base ownership newco name viatri
remainco strong growth profil justifi group-high price-to-earnings multipl view
current trade toward middl pack base price-to-earnings use consensu
estim exhibit artifici lower upjohn ep contribut
analyst remov base ep estim exclud upjohn
current trade price-to-earnings price target impli re-rat
valuat high-end peer
exhibit pfizer trade price-to-earnings note consensu ep
estim exclud upjohn trade peer averag
believ premium justifi best-in-class growth rate
model revenu ep cagr respect
shown exhibit closest comp revenu ep cagr
respect trade earn consensu estim
weigh growth begin pipelin strength stagger natur
help mitig impact
exhibit comparison large-cap biopharma revenu ep growth cagr
factset capit market estim
trade slightli four-year valuat rang per exhibit expect
re-rat higher post-upjohn deal close put simpli new complet
exhibit histor valuat chart share trade roughli standard deviat premium averag
differ entiti old term growth potenti expect valuat
adjust reflect
rel drg trade much cheaper today
begin much polit uncertainti head
elect year also provid greater degre downsid protect market
exhibit histor valuat chart contd drg trade within four-year averag discount
upjohn deal introduc new dynam valuat import understand
term agreement sharehold newco
/upjohn base estim newco share count price
target correspond billion valu per share use mylan
current share price right valu embed within share price pend
deal close deal close valu detach share much like
deriv cross-read keep focu
host compani watch deriv read call
import one focus exhibit rang partner
formal competit target pfizer import product vyndaqel
exhibit deriv cross-read focus
companyproductwhat watchcommentsibr therapeuticstrilaciclibphas data updat metastat tnbc inhibitor potenti competitor ibranc ibranc therapeuticslerociclibpivot bc trail expect initi phase studi bc estim primari complet date decemb inhibitor potenti competitor function readout develop pathway/lamb girdl timelin data competit direct competitor microdystrophin gene therapi program cover brian dmd phase i/ii trial hold updatedirect competitor dmd gene therapi program program clinic roxaparvovecphas updat result hemophilia phase studi hemophilia estim primari complet date decemb competitor hemophila collabor sangamo studi hemophilia estim primari complet date march competitor hemophila collabor sangamo patisiran apollo trialttr protein silenc potenti vyndaqel competitor phase trial start sept target attr-cm indic current market trialsttr protein silenc potenti vyndaqel competitor helio enrol primari endpoint month phase studydirect competitor tafamidi ttr trial attr-cmdirect competitor tafamadi ttr stabil expect fulli enrol phase top-lin data attr-cm month studi attr amyloidosi estim primari complet date novemb develop moa deplet misfold ttr protein would treatment paradigm gileadfilgotinibfda approv ra eu ra approv select phase data uc select inhibitor competitor xeljanz cover brian abraham
catalyst calendar limit post recent approv watch competitor data
datewhat eu supplement approv japan supplement approv phase pneumococc vaccin nave adultspfeprimari phase trial adult yr prior pneumococc vaccinationpfeprimari snda pdufa colorect cancer pfefirst vs dupix head-to-head phase readout jade compar pfehead-to-head vs dupix phase select data ucgildrinvoq competitor data pipelin phase extens studi readout axspallyprimari phase data gastric phase studi initi duchenn muscular dystrophypfepipelin gene therapi program pearl phase data breast oa oa pain bla ra supplement chmp opinionpfemodifi releas mg updat vg/kg dose phase data psoriat phase divers enrol complet cdglpg/gildrinvoq phase palla studi palbociclib adjuv endocrin therapi ebcpfeintermedi risk report enrol interim time rheumatoid arthriti post-market studi resultspfeprimari phase data psoriasisbmyor inhibitor jak famili studi phase data hemophilia phase patina studi palbociclib mbcpfeboth phase penelop studi palbociclib ebcpfehigh risk relaps neoadjuv interim time phase data psabmyor inhibitor jak famili difficil vaccin phase eu approv rheumatoid arthritisglpg/gildrinvoq phase readout ankylos hspc embark phase readout phase ole data hickori data ucrhhbyi competitor target laurel gardenia data ucrhhbyi competitor target ra comerci eugildrinvoq phase ixora-r studi readoutlli
import risk consid rel rate price target
biggest risk stock compani abil back-fil set hit
littl debat around execut risk
around deal relat well rel stock near-term posit ibranc
adjuv data palla studi next year get signific focu
impact street forecast final like peer watch drug price legisl
washington year could impact particularli given pfizer part
tail valu risk follow upjohn deal limit loss exclus loe
concern acceler manag expect million
less loe impact portfolio overli lever
singl product clearli runway ahead high
concentr key growth driver come patent late
prevnar eliqui xtandi ibranc vyndaqel
compani state interest continu capit deploy toward
acquir mid-stag asset could launch help mitig outer-year
busi develop risk given expect remain activ busi
develop find attract target convert commerci opportun
remain focu also think abil identifi execut deal
play sentiment around stock given focu smaller bolt-on type deal
like like limit risk mega-merg pursuit
seen recent peer
pipelin risk highlight initi blockbust
approv five year sever key read expect
come year see exhibit full pipelin chart particularli focus
ibranc adjuv metastat breast cancer read-out palla penelop
adjuv opportun compris ibranc revenu estim
includ risk-adjust furthermor earlier stage compani also
introduc key next-gener pipelin program critic sustain
growth beyond look loe concern start acceler late
level pipelin product key swing factor
regulatory/polit risk sever propos bill around drug price
reimburs add uncertainti potenti risk group price
driver growth us/glob price portfolio low singl digit
prior year focus propos could add pressur
portfolio particularli chang medicar
financi model revenu build balanc sheet cash flow forecast
exhibit intern medicin revenu build
 revenu segmentintern medicineeliqui apixiban eliqui model comp/matt expir book sale pay pradaxa bi xarelto warfarinchantix/champix vareniclin approv eu/u japan basic patent expir apotex eu basic product patent expir famili pressur women health initi higher neoplasm rate patient support low dose version dose oaunit pdufa eu japanal intern medicin includ new pipelin lineunit intern medicin unit intern medicin intern
exhibit oncolog revenu build
 revenu segmentoncologyibr palbociclib letrozol mbcunit refractori await ext adjuv read sunitinib basic product patent expir eu basic product patent expir enzalutamid deal appr pdufa mcrpcunit low teen low astella royalti ousxalkori crizotinib aug posit nsclc nsclc alecensa roch take share watch repotrectinib bosulif bosutinib us cml resist prior therapyunit ph cml dec ph cml apr axitinib basic product patent expir eu basic product patent expir epogen/procritunit biopharma acquisit close avastin bevacizumab unit launch rituxan rituximab unit launch jan herceptin trastuzumab unit launch oncolog pipelin pipelin contributionunit oncolog oncolog unit oncolog
exhibit hospit revenu build
 revenu segmenthospitalsulperazon launch back linezolid antibiot gram infectionsunit launch gener launch eu centreon anti-infect tygacilunit hospit includ new pipelin lineunit use plug hospit unit hospit
exhibit vaccin immunolog revenu build
 revenu segmentvaccinesprevnar guidelin neg impact launch behind adult mo continu low singl digit growthfsme/immun-ticovac vaccin pipelin pipelin contribut difficil etc unit vaccin vaccin unit vaccin revenu see modest growthinflamm immunolog xeljanz tofacitinib inhibitor us patent expir ex-pedunit ra blackbox adj similar warn ema uc enbrel etanercept ra ia adult plaqu patent expir biosimilar launch remicad su launch launch basic product patent expir launch ad risk-adjust pipelin pipelin contributionunit unit inflamm
exhibit diseas revenu build
 revenu segment diseasebenefix af/xyntha pegvisom tafamadi amyloid cardiomyopathi attr-cmunit loe potenti attr-fap polyneuropathi diseas pipelin pipelin contributionunit diseas diseas unit diseas biopharma unit biopharma differ biopharma
exhibit upjohn revenu build
 revenu segmentlyrica loe juli lipitor china impact china impact upjohn upjohn unit upjohn differ expect close
exhibit biopharma upjohn segment build
 revenu segmentintern immunolog product gm oper analysi segment revenu product assum step-up array oper analysi oper segmentseg myl/upjohn deal close product oper analysi segment revenu product oper analysi oper
exhibit corpor unalloc segment build
 revenu unalloc product analysi total revenu product analysi net cost product
exhibit
 incom model compound-annual-growth-rate myl/upjohn deal closeconsum effect guid billioncost product guid revenuegross profit guid guid billionoper incom intang healthcar jv ep annual gsk jv peak margin incom expens bs model includ expens incom othertot incom expens guid million incomeearn incom tax jv mid/high om stakeincom tax guid earn non-controlling earn ep guid share share reflect repodividend per cut upjohn close incr yield base price base price targetebitda estimateebitda run post upjohn expect increas post upjohn base year ex-upjohn margin expansionibt move low improvingtax guid profit analysi net share per
exhibit balanc sheet
 balanc cash boost proceedsshort-term cash st account receiv current held current plant equip intang asset non-current equityshort-term account tax compens relat current held current absenc deal visibl assum reductionpens benefit oblig benefit oblig defer tax tax non-current paid-in comprehens sharehold attribut non-controlling liabil
exhibit flow
 statement item includ net intang reportasset write-off compens adjust work account account tax account flow oper properti plant expect capital-expenditure post upjohnnet chang short-term chang long-term busi upjohn array acq intang invest activ flow invest chang short-term chang long-term support array acquisitionpurchas common dividend dividend rangeproce exercis stock financ activ flow financ exchang rate chang chang cash equival begin differ equival end cash equival ex
appendix deeper look vyndaqel expect rapid uptak
street like opportun vyndaqel success tie pfizer
abil boost diagnosi drug approv may bring ttr
stabil first approv therapeut wild type hereditari form
transthyretin amyloidosi cardiomyopathi attr-cm competitor program still
year market moreov think mechan action uniqu class small
molecul limit concern loss market share competitor biggest hurdl
drive awar given thu far track better expect
earli launch overal model billion world-wide vyndaqel sale
attr-cm rare fatal diseas limit treatment option attr-cm occur
breakdown ttr tetram protein monom form pathogen aggreg
variou region bodi includ cardiac tissu attr-cm build-up
pathogen misfold ttr protein caus tissu dysfunct death year median
surviv hattr-cm year wtattr-cm base natur histori maurer et al
patient typic experi progress heart failur problemat
perspect misdiagnosi addit diseas wide understood
diagnosi burdensom cardiac biopsi current gold standard
advanc educ effort around diagnosi
biomark artifici intellig incorpor diagnost algorithm develop
improv detect ttr-relat diseas treatment option asid vyndaqel
limit includ onpattro off-label tegsedi off-label rare case liver
transplant patient wtattr-cm diflunis tafamadi current
treatment option prevent plaqu format howev note diflunis hold
potenti safeti risk associ chronic usag non-steroid anti-inflammatori
current
see wide use vyndaqel attr-cm treatment paradigm think physician
comfort tafamadi oral small molecul stabil due
conveni dose decreas risk immunogen oppos mrna silenc
program furthermor survey exhibit indic physician see
prescrib vyndaqel attr-cm patient compar sirna
antisens oligo although earli expect given natur vyndaqel properti
oral small molecul long term due differ mechan action
think field move direct combin regimen target upstream ttr
mrna downstream ttr protein applic silenc stabil approach
could potenti deepen therapeut respons extend patient year surviv beyond
median surviv year report retrospect studi attr-cm patient
receiv ttr stabil diflunis tafamadi maurer et al
exhibit physician survey vyndaqel
oct averag wild type hereditari attr-cm neuropathi primarili use cardiac primarili use resourc unfamiliar responseswhat percentag frequenc transtheyretin amyloid cardiomyopathi attr-cm diagnosi within practic follow patient group last month believ wild-typ develop market hereditari hereditari continu diagnos higher level consist survey diagnos transtheyretin amyloid cardiomyopathi attr-cm encourag extent cardiologist survey familiar attr-cm resourc diagnos scintigraphi primari dianost tool anticip last month mani patient diagnos transthyretin amyloid cardiomyopathi attr-cm major physician diagnos fewer patient last year underscor need broad educ diagnos patient attr-cm last suggest opportun target high volum rel attr-cm physician scale like like recommend scintigraphi upon present patient year age cardiac wall thicken heart failur pose question anoth way ask physician like come conclus attr-cm could present sympton given under-diagnos diseas state answer somewhat map roughli two-third highli like higher recommend scintigraphi present wall thicken heart failur
exhibit physician survey vyndaqel continu
oct tafamidi oral qd dose transthyretin stabil select bind transthyretin stabil patisiran iv infus week ds-sirna caus degrad mutant wild type ttr inotersen subcutan dose weekli antisens oligonucleotid caus degrad mutant wild type ttr mrna black box warn risk thrombocytopenia tafamidi oral qd dose transthyretin stabil select bind transthyretin stabil patisiran iv infus week ds-sirna caus degrad mutant wild type ttr inotersen subcutan dose weekli antisens oligonucleotid caus degrad mutant wild type ttr mrna black box warn risk thrombocytopenia subcutan dose quarterli rnai target transthyretin somewhat surpris close one-third would still point option attr-cm patient vydaqel tafamidi approv therapi market expect degre competit current approv polyneuropathi treatment though slightli higher expect responsesthi clearli speak work educ cardiologist avail use vyndaqel tafamidi scale highest pleas rate familiar vyndaqel tafamidi assum onpattro tegsedi vutisiran fda approv treat wild type hereditari form transthyretin amyloid cardiomyopathi attr-cm often would prescrib list therapi attr-cm pleas notat answer percentag use per year answer chang much ask option drug current approv polyneuropathi also approv attr-cm recent fda approv vyndaqel/vyndamax hereditari wild type transthyretin amyloid cardiomyopathi attr-cm follow reflect view chang futur diagnosi rate attr-cm encourag extent half expect increas diagnosi anoth still expect increas current vyndaqel tafami fda approv treatment wild type hereditari form transthyretin amyloid cardiomyopathi attr-cm assum onpattro tegsedi would use label often would prescrib list therapi attr-cm patient pleas notat answer percentag use per year
biggest driver model come abil find patient
forecast detail product model exhibit estim
develop market preval could high rang unknown
diagnosi rate notabl low assum patient us
wild hereditari diagnosi rate start low climb annual slightli
higher hereditari given genet natur vyndaqel penetr estim may
conserv annual wac take lot patient drive
tafamadi modelest estimate estimate estimate estimate estimate estimate commentsattr-cm transthyretin amyloid cardiomyopathyu popul destabil transthyretin protein amyloid fibril growth heart caus stiff heart failuremedian life expect diagnosi yrsattr-cm wild-typ hereditari attr-cm incid use hf incid rateu patient attr-cm estimate us debat around real incidencemort rate mo mortal rate treat pbo blend patient death wtattr-cm associ age patient diagnosi rate scintigraphi big swing factortreat wtattr-cm patient past benchmark rare diseas penetr therapi current approvedtot wtattr-cm patient patient much smaller race prevalencediagnosi rate patient awar sinc hereditari treatabl hattr-cm patient penetr rnai competitor pipelin approvalstot hattr-cm patient discontinu year phase factor patient mortal start datesu attr-cm us attr-cm sale growth assumptionswac per wac price set upon launchpric chang best estim net price growthgross net medicar com medicaid/othnet price per vydamax net price per total sale indicationdollar millionsattr-cm hereditari us sale total salestot ou sale japan cm ema review growth sold ema patient estimate develop marketstot ww sale
competitor program monitor still year away data
read get attr-cm therapi group three separ group silenc
stabil disruptor although acknowledg scientif novelti within
platform think differ mechan action drug class reduc
concern around loss market share overal see key competit advantag
vyndaqel oral small molecul first market posit inclus wild type phenotyp
attr-cm popul clear clinic benefit regardless watch
progress sever program look target hereditari wild type attr-cm per
exhibit includ alnylam onpattro phase apollo-b studi initi
sept compani guid launch time-frame alnylam
vutrisiran phase helios-b studi enrol expect complet
compani guid launch akcea-ttr-lrx/ion-ttr-lrx
phase studi collabor ioni still earli two-part
attribute-cm phase studi eido guid part although earli also
watch phase studi hereditari attr-cm close watch believ
similar mechan action add potenti risk tafamidi market share
regardless littl data disclos think earli posit tafamidi reduc
concern competitor threat deriv cross-read tabl exhibit
appendix deeper look ibranc palbociclib adjuv key growth
see stabl growth profil ibranc driven expand inhibitor use
mbc metastat breast cancer product like maintain major
share meaning minor patient still receiv hormon monotherapi across
line therapi focu convert late-adopt provid tailwind
growth howev meaning growth opportun driven approv
uptak adjuv use earli breast cancer given much larger patient popul
longer durat also like first market assum posit data phase
palla penelop trial popul report enrol progress
primari complet slate late data expect read late earli
phase neoadjuv data pallet show promis result though
signific differ clinic respons suppress marker malign
cell prolifer signific palbo combin arm continu risk-adjust
estim likelihood success suspect contribut
adjuv opportun street number think potenti meaning
upsid remain underappreci reflect meaning catalyst
modest growth mbc continu late-adopt convert estim
patient receiv hormon monotherapi despit strong paloma data
demonstr meaning improv median benefit month
palbo arm almost five month patient
progress prior endocrin therapi though physician concern/reluct
around treat certain patient ie older patient viscer diseas
aggress focu educ lead expans within class rel
cleaner ae profil ibranc coupl first-mov advantag continu
next leg growth continu intern uptak remain
rel earli life cycl ibranc approv countri reimburs
intern sever market includ japan china brazil
class new patient start ibranc major share
japan class new patient start launch brazil china expect
import driver growth beyond rel underpenetr
class well smaller share within clear opportun though
temper lower price point rel limit lead market europ
kisqali approv shortli ibranc appear weigh share
bigger potenti opportun adjuv use earli breast cancer data expect
late address popul doubl metastat
potenti longer durat therapi palla year label expans
popul clearli import growth opportun ibranc also like
first-mov popul verzenio monarch follow close behind expect
data kisqali expect file earli palla penelop
posit continu risk-adjust estim pend data see potenti
billion revenu risk-adjust likelihood success
repres high teen penetr intermedi risk popul high high
ibranc inhibitor approv r/r treatment
metastat breast cancer mbc patient first market remain clear market
leader subsequ launch novarti kisqali lilli verzenio
fail take meaning share see exhibit differ
three non-trivi similar hazard ratio meant prescrib decis
larg guid toxic profil
exhibit ibranc retain major share despit entri verzenio kisqali
share -monthli trxibranceverzeniokisqaliibrancescript plateau recent month around mid share rang
addit first-mov advantag ibranc rel less burdensom ae profil
continu preserv
domin posit hematolog malign ie
neutropenia promin ae ibranc similarli high kisqali though
larg manag contrast addit high neutropenia kisqali also associ
hepatotox requir monitor liver function test lft well qt
interv prolong requir monitor ecg verzenio associ diarrhea
greatest first month therapi median durat grade diarrhea
day monarch also associ hepatotox requir monitor
lft
two primari growth driver focu expans inhibitor
use mbc popul point elig patient use cdk
rest use hormon monotherapi chemotherapi expans
adjuv use earli breast cancer
expans inhibitor class
expect expand use inhibitor continu provid modest tailwind
growth clearli still room expans focus convert
patient estim util hormon monotherapi note top
 account quarter use hormon monotherapi patient
given obviou benefit combo median month vs
month letrozol median month vs month letrozol
median month vs month fulvestr continu educ
driver expand use overal surviv os month follow-up
shown numer benefit month palbo arm though eli lilli verzenio
shown signific benefit month novarti kisqali also show signific
improv yet reach median os vs month saw
similar result achiev median os vs month control arm
physician discuss support expand use indic rare patient
would use inhibitor area clearli remain
patient viscer diseas patient popul
often treat
chemotherapi although absent symptomat viscer crisi evid
improv outcom combo therapi popul analysi
trial show benefit patient viscer metastas patient
without prior resist hormon therapi
ii older patient recent pool analysi compar
treatment patient yr show similar efficaci combo
therapi estim median time month younger patient
month hazard ratio although group experienc higher toxic
incid grade vs year higher dose
reduct discontinu commonli due neutropenia diarrhea increas
creatinin patient year compris new case us
howev frequent concern insur coverage/out-of-pocket cost
patients/reimburs respond point hurdl expand
use
adjuv use earli breast cancer patient meaning potenti growth
opportun doubl address patient popul phase palla import
trial broader popul enrol intermedi high risk patient penelop
high risk studi expect complet late opportun
meaning given larger size potenti longer durat treatment expect
discontinu rate dose modif rate key swing factor given
potenti cur patient popul see risk toler differ
sensit lower grade toxic could impact qualiti life diarrhea
fatigu phase neoadjuv data pallet show suppress
valid marker treatment benefit shown predict recurrence-fre surviv
er diseas pend visibl pallas/penelop trial maintain
risk-adjust likelihood success
exhibit upcom trial updat watch
sale world-wide reach billion estim
billion palla adjuv data read posit expect could still
conserv detail forecast exhibit adjuv contribut
billion risk adjust think could conserv
trialphaseprimari completionpopulationprimari endpoint catalyststudi idibrancepallasphas breast cancer stage ii/iii intermediate/high risk earli bc men/women pre/post menopausalinvas diseas free surviv time frame yr report enrol interim trial expect run complet read-out late yr neoadjuv mbc men/womenpf time frame bphase residu diseas neoadjuv chemo/surgeri high-risk earli bc pre/post menopaus womeninvas diseas free survivalreport enrol interim time unknown trial complet yr neoadjuv high risk earli bc women/men pre/post menopausalinvas diseas free surviv time frame recurr death caus yr data earli bc adjuv trial pre/post menopaus men/womeninvas diseas free surviv time frame yr registr could earli
us ibranc femal popul us male popul us popul growth rate year-over-year palbociclib bc assumptionspreval rate mbc ribociclib-nv appr differ preval mbc mariotto et alincid rate invas bc start stage i-iiaincid invas bc bc death rate neo-adj suppress biomarkbc-rel mortal note ibranc neutropenia ae high discon lumin see lumin see belowtripl neg tnbc ht chemo target lumin endocrine/cdk de novo fulvestr tamox aromatas inh uptod de novo recurmbcincid mbc paloma estimate treatment appr roch epidemiologypenetr treatment appr roch epidemiologypenetr patient ibranc average month mo modiscontinu rate mth median cycl ibranc revenu mbc loe ext file accept growth bc adjuv assum approv late readoutsincid ebc doubl mbc longer durationintermedi risk earli diseas higher risk high risk early-stag er bcadjuv penelope-b palla int risk patient pt read high risk patient endpoint dsf read bothincid hr /her- earli adj per adjuv could doubl patient vernezio adjuv read-out penetr penetr high greater penetr high-risk ptsdiscontinu rate d/c rate registr clinic trialsearli bc patient ibranc adjuv oppti initi mbcadjuv target stage month cycl penelop yr pallasu ibranc adjuv revenu growth ibranc adjuv risk assumptionsibr monthli price per net price increas assum gross net qd day day treatmentnet price per month per millions ibranc revenu growth year-over-year sale growth total
appendix deeper look prevnar focu approv
prevnar account vast major revenu vaccin franchis
compani singl largest product overal prevnar approv prevent
pneumococc pneumonia invas diseas caus streptococcu pneumonia
strain pneumococc bacteria
lead caus bacteri pneumonia caus infect includ bacteremia
sepsi mening immun recommend cdc children age
month via immun seri well adult immunocompromis
condit via singl dose children prevnar sole pneumococc
vaccin recommend cdc adult also recommend vaccin
case combin merck pneumovax collect
contribut domin market share posit prevnar us go along
meaning intern revenu expect competit dynam shift time
next-gener vaccin introduc base case assumpt pfizer
maintain lead market posit
cdc recent decis narrow prevnar recommend adult
year introduc modest headwind june meet advisori
committe immun practic acip vote recommend share clinic decis
make vaccin adult immunocompromis
previous receiv downgrad committe broader
guidanc recommend adult year
previous receiv year recommend chang base part
evid chang invas pneumococc diseas ipd incid
among adult year sinc direct indirect effect
observ popul level result decis model modestli declin
pcv vaccin rate among adult age year
assum vaccin rate begin climb follow introduct next-
gener vaccin importantli acip pcv recommend respect children
exhibit summari evolv cdc pneumococc conjug vaccin recommend
merck repres greatest threat lead market posit think
pfizer follow-on vaccin ultim win non-prevnar serotyp make
major invas pneumococc diseas ipd burden creat compel
market opportun next-gener vaccin furthest ahead merck
late stage develop pneumococc vaccin candid offer
protect two addit serotyp rel prevnar merck
run phase clinic trial variou adult pediatr higher risk popul
trial read adult trial earlier pediatr trial
later meanwhil candid includ serotyp contain
prevnar plu seven addit serotyp three
adult trial underway remain on-track file nda adult indic
end put believ around six month behind merck farther
behind pursuit pediatr indic expect begin phase
estim place month behind merck given superior number
serotyp view transitori setback
model flat world-wide revenu prevnar franchis
compris prevnar per market model exhibit
us model declin revenu driven lower adult
vaccin rate due new acip guidelin see ii lower pediatr
vaccin due declin fertil rate assum revenu stabil begin
launch drive higher adult vaccin rate off-set modest share loss
vaccinecompanynumb serotypesind develop statuslaunch timingupcom milestonesmileston timingcommentspneumovax approv pediatr useprevnar current market leader pediatr adult populationsadultphas completionearli expect first next-gener pneumococc vaccin reach market earli final pediatr studi expect read believ get market within six month merck month behind merck pediatr use tailor adult popul expect cover vast major residu diseas
merck assum stabl net price throughout forecast period
prevnar intern market model mid-to-low singl digit growth
forecast period suffici off-set us weak drive
expect stabl world-wide revenu
modelactualest estimate estimate estimate estimate estimate estimate commentsunit statesu popul year us censu bureaugrowth rate mortal rate nci seer program datapneumococc vaccin rate interview surveyw assum decreas due acip changevaccin long recommend adult assum increas next-gen introductionstot annual dose one dose adultsu popul us censu bureaugrowth rate risk popul smoker diabet estimatepneumococc vaccin rate interview surveyvaccin behind adultstot annual dose one dose adultstot number us cdc nation vital statist reportsgrowth rate vaccin rate estimatenumb acip guidelinestot annual dose market share launch mo behind pediatrictot dose prevnar assum switch prevnar upon launchlist price per price rxprice chang net price per stabl net pricingtot us revenu prevnar prevnar growth growth growth rest growth growth growth growth revenu growth growth world-wide revenuetot prevnar revenu growth
emerg headwind weigh growth expect prevnar remain leader
pneumococc vaccin categori prevnar reliabl revenu driver
compani singl largest product biopharma group
revenu prevnar pneumococc conjug vaccin use prevent
infect caus pneumococc bacteria cdc recommend use children
certain high-risk adult forecast slow growth come year in-
line street consensu dig deeper model low-singl digit growth intern
off-set declin sale us sever factor behind us weak
includ acip june revers previou recommend adult age
older receiv prevnar acip recommend share clinic decis make
also expect merck vaccin enter market come year
expect modest impact said believ pfizer next-
gener vaccin superior allow retain
major market share
watch primari focu continu clinic develop
view critic sustain franchis includ serotyp
contain prevnar plu seven addit serotyp recent announc posit
preliminari result proof-of-concept phase pediatr studi studi complet
expect earli enabl compani begin phase pediatr trial
adult indic expect submit bla end
subject success complet three on-going phase adult studi also
watch develop merck vaccin multipl phase read-
out expect merck addit pneumococc conjug vaccin
develop behind includ tailor specif adult market littl
disclos
appendix deeper look xeljanz see stabl growth late
xeljanz market leader jak inhibitor rheumatoid arthriti initi approv
treat rheumatoid arthriti xeljanz stabl grower
focu impact black box warn addit well
addit competit ahead anticip gener entri late
exhibit xeljanz summari revenu forecast indic
modelactualest estimate estimate estimate estimate estimate estimate commentstot us revenu indicationdollar millionsse detail market model indicationrheumatoid arthriti arthriti quarter sale includ coliti blackbox impact uptakeankylos spondyl us revenu total revenuedollar millionstot ou revenu total revenuetot risk-adjust ww revenu
see recent black box warn meaning impact came
result post-market safeti studi rheumatoid arthriti patient report
greater risk blood clot death associ higher dose xeljanz mg bid
subsequ black box warn ad drug class seen approv
eli lilli olumi rinvoq although neg note mg bid
dose recommend treatment ulcer coliti think help
reduc safeti concern around xeljanz usag interestingli xeljanz wide
use jak inhibitor survey conduct rheumatologist also report
modest degre safeti concern around xeljanz usag think first market
posit larg data packag support continu wide use think larger
problem around competitor dynam novel jak inhibitor begin
commerci howev keep close eye prescrib demand script trend
monitor xeljanz uptak manag note neg impact guidanc outlook
earn model stabl penetr rate modest
declin year account competitor launch
focu remain sever jak inhibitor program autoimmun therapeut
market competit multipl player develop pipelin product includ
recent approv rinvoq rheumatoid arthriti alreadi seen strong
uptak first quarter launch part indic expans effort
current run five phase trial rinvoq monitor timelin data read
commerci estim psoriat arthriti launch ulcer coliti
galapago collabor gilead develop oral inhibitor filgotinib
current phase trial rheumatoid arthriti ulcer coliti crohn diseas
galapagos/gilead plan nda submiss rheumatoid arthriti year follow
phase result ulcer coliti also monitor olumi oral
non-select jak inhibitor current approv rheumatoid arthriti r/r patient
xeljanz stabl growth expect continu loe per product model
exhibit xeljanz reach billion global across
rheumatoid arthriti psoriat arthriti ulcer coliti ankylos spondyl
howev gener expect enter late focu back-fil
sizabl loe xeljanz
tofacitinib modelactualest estimate estimate estimate estimate estimate estimate commentsu popul us censu bureau datagrowth arthriti ra us ra preval arthriti foundat datau patient ra sever preval et al sever ra patient refract/intol ra pt start csdmard et al csdmard penetr competitor enter markettr csdmard pt refract/intol ra pt start estim anti-tnf refractori radner anti-tnf penetr select jaki approvalstr anti-tnf ra pt anti-tnf refract/intol pt ra market share ra treat pt month discontinu treatment completionand pt deathsu ra ra revenu arthriti us psoriasi pso preval psoriasi foundat patient pso patient psoriasi foundationpati refract/intol patient start rheumatolog trialsxeljanz penetr penetr due black box concernstr pt refract/intol pt start biolog biolog refractori bayaraa biolog penetr biolog pt biolog refract/intol pt address pt market share treat pt averag month discontinu treatment completionand pt death revenu
tofacitinib modelactualest estimate estimate estimate estimate estimate estimate commentsu popul us censu bureau datagrowth coliti uc us uc preval patient uc moderate-to-sever uc preval estimatespati mod-to-sever uc refract/intol uc patient start estim et al penetr rate penetr due black box concernsxeljanz treat pt refractori uc patient start estim biolog et al biolog uc penetr penetr biolog failuresxeljanz biolog pt biolog refract/intol uc pt pt uc market share uc treat pt month discontinu treatment completionand pt deathsuc uc revenu spondyl us preval et al patient sever preval estim base ra estimatesmoder sever pt pt address pt market share treat pt averag month discontinu treatment completionand pt deathsa revenu revenu assumptionstablet xr formulationwac per price chang challeng futur price environmentgross net net price per price appli blend script incorpor xr formul use dataweight averag per tablet market share market share
appendix deeper look eliqui high margin contribut
eliqui apixaban oral anticoagul prevent clot format select
revers block activ clot factor xa eliqui jointli develop
commerci collabor bristol-my squibb profit loss
share equal global basi except eliqui member novel
oral anticoagul noac class drug recent supplant warfarin
prefer treatment patient atrial fibril af stroke prevent princip
prioriti af popul includ estim million peopl us
includ approxim peopl age year older vitamin antagonist
warfarin coumadin jantoven gener long standard care af
drawback includ narrow therapeut index requir regular blood test
drug/food interact noac eliqui requir regular blood test
fewer food/drug interact also demonstr noninferior efficaci safeti
compar warfarin benefit reflect updat aha/acc/hr
guidelin recommend noac prefer altern warfarin reduc
risk stroke
view eliqui best-in-class therapi within noac class reflect
market growth provid summari variou noac therapi plu warfarin
exhibit head-to-head clinic trial perform compar efficaci
noac versu noac howev next closest thing aristophan
observ studi conduct use pool claim data largest observ
noac studi perform date roughli patient across six match cohort
apixaban dabigatran rivaroxaban warfarin studi apixaban dabigatran
rivaroxaban associ lower rate stroke/system embol rel
warfarin moreov apixaban associ lower risk stroke/system
embol major bleed rel dabigatran rivaroxaban import
caveat aristophan studi fund bristol-my squibb
substitut head-to-head data nonetheless provid compel support
eliqui superior clinic profil believ help sustain market growth go
exhibit eliqui competit landscap summari oral coagul market
eliqui deriv meaning revenu medicar part program could leav
suscept drug price reform half eliqui revenu deriv
part program eliqui account second highest total part spend
drug outlook us drug price reform far clear believ
measur chang like within next year depend reform look
like could posit neg affect eliqui revenu go forward though see
bia downsid alreadi signific season impact us eliqui sale due
part coverag gap donut hole current law drug manufactur must pay
discount brand-nam drug coverag gap phase start
total drug spend end catastroph threshold hit
liabil contribut higher gross-to-net second half year
compar first half correspond decreas sale
model strong revenu growth roughli line consensu refer
market model exhibit us sever import assumpt
underli forecast assum overal oral anticoagul market continu
grow per year driven continu growth popul ii assum
noac continu take share warfarin iii assum eliqui continu
grow market share albeit modestli within noac class due best-in-class
clinic profil also model continu growth intern market greatest
nomin contribut come develop europ outlook beyond less
clear basic product patent expir year includ us eu japan though
addit patent may provid protect us gener compani
file paragraph iv challeng eliqui result settlement
term materi expect on-going area focu
expect gener entri
oral coagulantcompanyyear us approvalmechan actiondos frequencyfood effect us market share brand includ narrow therapeut index requir regular blood test drug/food interactionspradaxa dabigatran boehring thrombin fda-approv noac prodrugxarelto rivaroxaban bayer xa bayer healthcar johnson johnsoneliqui apixaban xa loss share equal bristol-my squibb global basi except savaysa edoxaban daiichi xa approv japan xa prevent vte patient hospit acut ill risk thromboembol complicationsnot dose frequenc list nonvalvular atrial fibril indic
watch competit develop program
believ challeng eliqui market leadership near intermediate-term instead
greatest threat could come drug price reform given eliqui signific relianc
us medicar part program account revenu visibl
low someth continu monitor anoth distant overhang
threat gener competit us eu japan basic product patent expir
least gener compani alreadi file paragraph iv challeng eliqui
us two receiv fda approv visibl low
expect see gener competit
apixiban modelactualest estimate estimate estimate estimate estimate estimate commentsunit statesor anticoagul marketvitamin antagonist noval oral anticoagul market iqviagrowth rate market share market share iqviaeliqui share noac market growth rate price per price rxprice chang net price per us revenue report basic product patent expir split paid profit/loss share equal total us revenue report growth eu basic product patent expir growth growth rest basic product patent expir growth growth growth growth revenue report growth growth world-wide revenueeliqui revenue report growth pfizer inc
